Business Wire

TX-FLUENCE

12.8.2021 14:02:08 CEST | Business Wire | Press release

Share
Fluence by OSRAM Reveals Multiyear Global Research Results on Broad-Spectrum Lighting Strategies for Cannabis and Food Crops

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the results from a series of multiyear global studies analyzing the effects of broad-spectrum white light on cannabis, Merlice tomatoes and bell peppers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005279/en/

The studies found that while spectrum sensitivity is cultivar-dependent, broad-spectrum lighting strategies—which include green light and other wavelengths largely absent in narrow-band spectra—improved crop yield, morphology and overall performance in selected cultivars when compared to narrow-band spectra with high ratios of red and far-red wavelengths.

“The results from our global studies show how effective broad-spectrum white light can be in improving crop performance for many cultivators around the world,” said Dr. David Hawley, principal scientist at Fluence. “Broad-spectrum strategies are about balance and flexibility in the spectrum itself as well as the overall cultivation approach. While there are certain scenarios in which narrow-band spectra, or pink light, may make sense from an energy efficiency or crop production perspective, we’ve found that many cultivars simply perform better under broad spectra across the KPIs cultivators care about most: yield, morphology and overall quality. Our latest research empowers us with new insights to assess each grower’s objectives, weigh those objectives against a facility’s unique financial, environmental and energy parameters, and then ultimately derive a tailored solution for each cultivator.”

Merlice tomatoes

A collaborative study with Wageningen University and Research (WUR)—led by researchers Leo Marcelis and Ep Heuvelink—evaluated differences in yield, morphology, development and quality for Merlice tomatoes grown with the VYPR top light series under four light spectra: PhysioSpecTM BROAD R4, PhysioSpec TM BROAD R6, PhysioSpecTM BROAD R8 and PhysioSpecTM DUAL R9B. BROAD R4, R6 and R8 all contain significant fractions of green light and other photosynthetically active wavelengths, while DUAL R9B is a narrow-band spectrum that contains almost no green light.

As researchers increased the ratio of red light in the overall spectrum, they recorded a linear decrease in yield. Compared to spectra with higher blue, red and far-red wavelengths, Merlice grown under broader spectrum lights yielded increases in fruit weight as high as 13 percent. Other tomato cultivars grown under broad-spectrum saw yield increases up to 14 percent.

Cannabis

Fluence conducted individual studies with WUR and Texas Original Compassionate Cultivation (TOCC), respectively. In the TOCC study, researchers studied Type I, Type II and Type III cannabis response to broad-spectrum R4, R6 and R8 under high PPFD. In each case, broad-spectrum R4 generated the most dry weight per plant. In Type I cannabis, PhysioSpecTM BROAD R4 generated 17 percent higher yields than the next highest yielding spectral solution, R6. Cannabis grown under broad-spectrum R4 also significantly improved morphology compared to plants cultivated under R6 or R8. Plants grown under broad-spectrum R4 were free of photobleaching in their upper buds, a development that typically occurs in plants grown with a higher fraction of red light.

In the WUR study, researchers found that in some cultivars, monoterpene and cannabinoid content, including THC, CBD and CBG, is significantly inversely proportional to the fraction of red light in the production spectrum. With these cultivars, R4 induced a 20 percent increase in cannabinoid compounds compared to spectra with red light ratios as high as 90 percent or more.

“The results of the TOCC and WUR intensity and spectrum studies are important for cannabis cultivators for two reasons,” Dr. Hawley said. “First, there is rarely a scenario in which they should grow cannabis under low PPFD. Our research continues to emphasize how much more beneficial it is to grow cannabis under higher PPFDs. Second, watch your red light ratio. There are a couple very specific cultivars and production situations that could benefit from narrow-band or high red/far-red and blue wavelengths. But it can also have detrimental effects on cannabinoid content, terpene ratios, yield and morphology, and would raise the risk of significant photobleaching of the canopy. That’s why we generally recommend growing cannabis with broad-spectrum under high PPFD.”

Bell pepper

Fluence also conducted studies with bell peppers at the Harrow Research and Development Centre in Ontario, Canada led by Dr. Xiuming Hao and Dr. Jason Lanoue. The collaborative research on bell pepper found that fruit quality significantly increased in Gina and Eurix cultivars under broad-spectrum lighting. Peppers grown under broader spectrum light increased average fruit size by up to 15 percent compared to others with higher blue and red wavelengths. An increase in the dry matter content—which is largely associated with fruit quality—also increased with increasing green light. It was also found that broad-spectrum lighting strategies proved the consistency of week-to-week production by leveling out a traditionally flush-prone crop cycle.

“Time and time again, our research with leading institutions around the world is proving that there is no universal spectral strategy for cultivators,” said David Cohen, CEO at Fluence. “For many crops and cultivars, however, it’s also showing the holistic benefits of broad-spectrum white light not just for the crop, but for a cultivator’s entire operation. That’s why we at Fluence have a multilayered approach to how we work with our cultivators. We continue to invest heavily in industry-leading research around the world. We provide cultivators with boots-on-the-ground expertise and experience in the form of our horticulture services team, and we identify the right light fixture and spectral strategy to help cultivators achieve their most important goals.”

Fluence’s ongoing global research initiatives include additional studies on strawberry, lettuce and cucumber cultivation. To learn more about Fluence and discover its latest research results, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye